Literature DB >> 11238859

Improved adenovirus vectors for infection of cardiovascular tissues.

M J Havenga1, A A Lemckert, J M Grimbergen, R Vogels, L G Huisman, D Valerio, A Bout, P H Quax.   

Abstract

To identify improved adenovirus vectors for cardiovascular gene therapy, a library of adenovirus vectors based on adenovirus serotype 5 (Ad5) but carrying fiber molecules of other human serotypes, was generated. This library was tested for efficiency of infection of human primary vascular endothelial cells (ECs) and smooth muscle cells (SMCs). Based on luciferase, LacZ, or green fluorescent protein (GFP) marker gene expression, several fiber chimeric vectors were identified that displayed improved infection of these cell types. One of the viruses that performed particularly well is an Ad5 carrying the fiber of Ad16 (Ad5.Fib16), a subgroup B virus. This virus showed, on average, 8- and 64-fold-increased luciferase activities on umbilical vein ECs and SMCs, respectively, compared to the parent vector. GFP and lacZ markers showed that approximately 3-fold (ECs) and 10-fold (SMCs) more cells were transduced. Experiments performed with both cultured SMCs and organ cultures derived from different vascular origins (saphenous vein, iliac artery, left interior mammary artery, and aorta) and from different species demonstrated that Ad5.Fib16 consistently displays improved infection in primates (humans and rhesus monkeys). SMCs of the same vessels of rodents and pigs were less infectable with Ad5.Fib16 than with Ad5. This suggests that either the receptor for human Ad16 is not conserved between different species or that differences in the expression levels of the putative receptor exist. In conclusion, our results show that an Ad5-based virus carrying the fiber of Ad16 is a potent vector for the transduction of primate cardiovascular cells and tissues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238859      PMCID: PMC114126          DOI: 10.1128/JVI.75.7.3335-3342.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Structure and expression of the human SM22alpha gene, assignment of the gene to chromosome 11, and repression of the promoter activity by cytosine DNA methylation.

Authors:  H Yamamura; H Masuda; W Ikeda; T Tokuyama; M Takagi; N Shibata; M Tatsuta; K Takahashi
Journal:  J Biochem       Date:  1997-07       Impact factor: 3.387

Review 2.  Prospects for human gene therapy.

Authors:  A Bout
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

3.  Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles.

Authors:  P W Shabram; D D Giroux; A M Goudreau; R J Gregory; M T Horn; B G Huyghe; X Liu; M H Nunnally; B J Sugarman; S Sutjipto
Journal:  Hum Gene Ther       Date:  1997-03-01       Impact factor: 5.695

4.  Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo.

Authors:  S Kim; H Lin; E Barr; L Chu; J M Leiden; M S Parmacek
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

5.  Detection of wild-type contamination in a recombinant adenoviral preparation by PCR.

Authors:  W W Zhang; P E Koch; J A Roth
Journal:  Biotechniques       Date:  1995-03       Impact factor: 1.993

6.  Green fluorescent protein as a marker for gene expression.

Authors:  M Chalfie; Y Tu; G Euskirchen; W W Ward; D C Prasher
Journal:  Science       Date:  1994-02-11       Impact factor: 47.728

7.  Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury.

Authors:  Z Y Yang; R D Simari; N D Perkins; H San; D Gordon; G J Nabel; E G Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  The migration of human smooth muscle cells in vitro is mediated by plasminogen activation and can be inhibited by alpha2-macroglobulin receptor associated protein.

Authors:  M J Wijnberg; P H Quax; N M Nieuwenbroek; J H Verheijen
Journal:  Thromb Haemost       Date:  1997-08       Impact factor: 5.249

9.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.

Authors:  F J Fallaux; O Kranenburg; S J Cramer; A Houweling; H Van Ormondt; R C Hoeben; A J Van Der Eb
Journal:  Hum Gene Ther       Date:  1996-01-20       Impact factor: 5.695

10.  Plaque changes and arterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment.

Authors:  J R Kaplan; S B Manuck; M R Adams; J K Williams; T C Register; T B Clarkson
Journal:  Arterioscler Thromb       Date:  1993-02
View more
  38 in total

1.  Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Authors:  M J E Havenga; A A C Lemckert; O J A E Ophorst; M van Meijer; W T V Germeraad; J Grimbergen; M A van Den Doel; R Vogels; J van Deutekom; A A M Janson; J D de Bruijn; F Uytdehaag; P H A Quax; T Logtenberg; M Mehtali; A Bout
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 2.  Targeting gene therapy vectors to the vascular endothelium.

Authors:  Lorraine M Work; Stuart A Nicklin; Andrew H Baker
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

3.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer.

Authors:  C E Appleby; P A Kingston; A David; C A Gerdes; P Umaña; M G Castro; P R Lowenstein; A M Heagerty
Journal:  Gene Ther       Date:  2003-09       Impact factor: 5.250

5.  Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches.

Authors:  Pete Murakami; Menzo Havenga; Farah Fawaz; Ronald Vogels; Giuseppe Marzio; Erno Pungor; Jim Files; Linh Do; Jaap Goudsmit; Michael McCaman
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3.

Authors:  Dominique Sirena; Benjamin Lilienfeld; Markus Eisenhut; Stefan Kälin; Karin Boucke; Roger R Beerli; Lorenz Vogt; Christiane Ruedl; Martin F Bachmann; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Authors:  Lennart Holterman; Ronald Vogels; Remko van der Vlugt; Martijn Sieuwerts; Jos Grimbergen; Jorn Kaspers; Eric Geelen; Esmeralda van der Helm; Angelique Lemckert; Gert Gillissen; Sandra Verhaagh; Jerome Custers; David Zuijdgeest; Ben Berkhout; Margreet Bakker; Paul Quax; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

9.  The distal short consensus repeats 1 and 2 of the membrane cofactor protein CD46 and their distance from the cell membrane determine productive entry of species B adenovirus serotype 35.

Authors:  Christoph Fleischli; Sandra Verhaagh; Menzo Havenga; Dominique Sirena; Walter Schaffner; Roberto Cattaneo; Urs F Greber; Silvio Hemmi
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 10.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.